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Abstract
Objectives: The objective was to evaluate safety of intravenous (IV) tissue plasminogen activator (tPA)
delivered without dedicated thrombolytic stroke teams.
Methods: This was a retrospective, observational study of patients treated between 1996 and 2005 at
four southeastern Michigan hospital emergency departments (EDs) with a prospectively defined compar-
ison to the National Institute of Neurological Disorders and Stroke (NINDS) tPA stroke study cohort.
Main outcome measures were mortality, intracerebral hemorrhage (ICH), systemic hemorrhage, neuro-
logic recovery, and guideline violations.
Results: A total of 273 consecutive stroke patients were treated by 95 emergency physicians (EPs) using
guidelines and local neurology resources. One-year mortality was 27.8%. Unadjusted Cox model relative
risk (RR) of mortality compared to the NINDS tPA treatment and placebo groups was 1.20 (95% confi-
dence interval [CI] = 0.87 to 1.64) and 1.04 (95% CI = 0.76 to 1.41), respectively. The rate of significant
ICH by computed tomography (CT) criteria was 6.6% (odds ratio [OR] = 1.03, 95% CI = 0.56 to 1.90 com-
pared to the NINDS tPA treatment group). The proportions of symptomatic ICH by two other prespeci-
fied sets of clinical criteria were 4.8 and 7.0%. The rate of any ICH within 36 hours of treatment was
9.9% (RR = 0.94, 95% CI = 0.58 to 1.51 compared to the NINDS tPA group). The occurrence of major sys-
temic hemorrhage (requiring transfusion) was 1.1%. Functional recovery by the modified Rankin Scale
score (mRS = 0 to 2) at discharge occurred in 38% of patients with a premorbid disability mRS < 2.
Guideline deviations occurred in the ED in 26% of patients and in 25% of patients following admission.
Conclusions: In these EDs there was no evidence of increased risk with respect to mortality, ICH, sys-
temic hemorrhage, or worsened functional outcome when tPA was administered without dedicated
thrombolytic stroke teams. Additional effort is needed to improve guideline compliance.
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O f over 650,000 patients with ischemic stroke inthe United States each year,1 15% to 27%2–4present to hospitals within the 3-hour time win-
dow necessary to receive intravenous (IV) tissue plasmin-
ogen activator (tPA), and 11.5% are estimated fully
eligible for treatment.5 Fewer than 2%, however, are
actually treated.3,6,7 Reasons for the low practice pene-
tration of thrombolytic therapy include limited data on
tPA safety when used outside of acute stroke teams and
the operational constraints on creating acute stroke
teams at most community hospitals.
Of 19 published case series4,8–25 on postapproval use
of tPA in stroke, nine definitively note any thrombolytic
delivery using a ‘‘community model’’ of thrombolytic
delivery—where tPA is administered by physicians,
including non-neurologists, outside of an acute stroke
team.4,8,10,11,18,20,22,23,25 Six studies identified instances
of delivery by an emergency or primary care physician
(either alone or with telephone consultation with a neu-
rologist).8,18,20,22,23,25 The number of patients treated by
non-neurologists in these, however, was small—ranging
from 6 to 53. Two studies reported cautionary findings
for ‘‘community models’’ of acute stroke care. One
noted an increase in symptomatic intracerebral hemor-
rhage (ICH) in a series of 70 patients treated by
community neurologists,4 and both found increased
in-hospital mortality among tPA-treated stroke
patients.4,11
Thus, evidence on the safety of thrombolytic delivery
in a common U.S. hospital setting—an emergency
department (ED) without a stroke team that uses local
neurologic resources—is quite limited. This potentially
contributes to a failure of second-stage knowledge
translation in moving randomized controlled trial find-
ings to common clinical practice.
The objective of this study was to evaluate the safety
of IV tPA use in stroke patients when delivered without
a dedicated acute thrombolytic stroke team in a cohort
of four hospitals. We prospectively defined historical
comparison to the National Institute of Neurological
Disorders and Stroke (NINDS) tPA stroke study to place
the findings in context to results achieved by dedicated
stroke researchers. In the comparison, safety was
defined as 1-year mortality and short term disability no
worse than the NINDS placebo group and significant
ICH no more frequent than symptomatic ICH in
the NINDS treatment group. Survival analysis, as well
as mortality at common stroke endpoints (3 and
6 months), is provided for all cohorts.
METHODS
Study Design
This was a retrospective observational cohort study
with prospectively defined comparisons to the NINDS
tPA stroke study cohort. Each participating hospital’s
institutional review board approved the study prior to
data collection.
Study Setting and Population
Four secondary and tertiary care hospitals in a contigu-
ous, four-county region of southeastern Michigan
participated in the study. In 1996, each hospital imple-
mented a program for emergency physician (EP)-
directed stroke treatment using existing resources and
neurology consultation as available at each facility,
rather than developing an acute stroke response team.
The presence of a neurologist or stroke specialist was
not required prior to treatment. The hospitals and their
physician staffs are independent entities; however, the
EDs had affiliations with the University of Michigan
over the time course of the study. None of the involved
hospitals were designated primary stroke centers dur-
ing the time period of the study; however, three have
subsequently become Joint Commission–certified cen-
ters. A stroke research team, enrolling subjects at two
hospitals (in Ann Arbor only), was available to any of
the hospitals for phone consultation regarding tPA use
during the study period, but was not responsible for
providing standard IV tPA treatment (see Table 1 for
hospital and ED characteristics and Data Supplement
S1, available as supporting information in the online
version of this paper) for further detail. All patients
identified as treated with IV tPA for presumed ischemic
stroke from a participating hospital ED between Janu-
ary 1, 1996, and January 1, 2005 were included.
Study Protocol
Four methods (billing data, pharmacy logs, hospital
stroke registries, and Paul Coverdell National Acute
Stroke Registry data)26 were used for case identification





1 2 3 4
Location—city Ann Arbor Ann Arbor Flint Jackson
Urban ⁄ rural ⁄ suburban Suburban Suburban Urban Rural
Hospital beds (2004) 792 529 463 411
ED visits per year (2004)* 50,918 65,259 54,707 52,500*
Neurology residency Yes No No No
Emergency medicine residency Yes Yes Yes No
tPA-treated cases, n (%) 79 (29) 127 (47) 17 (6) 50 (18)
tPA = tissue plasminogen activator.
*For hospitals 1, 2, and 3, this represents adult ED visits only; for hospital 4, this represents total pediatric and adult visits.
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Patients initially evaluated or treated in the ED at a
nonparticipating hospital and subsequently transferred
to a study hospital for treatment or management were
included in the destination hospital at analysis.
Study coordinators, with stroke experience and
trained in both NIH Stroke Scale and modified Rankin
Scale (mRS) administration (using internationally accep-
ted clinical trial certification materials and tests),
confirmed stroke treatment with IV tPA prior to data
abstraction. They subsequently reviewed each con-
firmed case using all available hospital and ED paper
and ⁄ or electronic medical records.
Medical records were then abstracted using a paper
data collection form with 148 separate elements (Data
Supplement S2, available as supporting information in
the online version of this paper) and transferred to an
electronic database using double-data entry. Data defi-
nitions and decision rules were adapted with permis-
sion from the Michigan prototype of the Paul Coverdell
stroke registry.
All radiology reports of neuroimaging (computed
tomography [CT] or magnetic resonance imaging
[MRI]) performed within 10 days of thrombolytic treat-
ment were reviewed. All available CT and MRI images
were collected for patients in whom any report
described the presence of an intracranial finding other
than those directly resulting from ischemic stroke,
including, but not restricted to, any suggestion of
an ICH.
Twenty percent of charts from each site were system-
atically selected for dual data abstraction by indepen-
dent reviewers to assess interrater agreement. Ten
percent came from the oldest charts (by stroke treat-
ment date) at each site on the basis that these would be
most likely to be difficult to read or have missing data
elements. An additional 10% were selected from the
remaining charts at random. Disagreements between
reviewers were adjudicated by physician investigators
(PAS, RS) using the process described in Data Supple-
ment S1.
Neuroimaging Assessment. To identify and classify
ICH, two neuroradiologists (SAA, DPL), blinded to
treatment course and other interpretations, completed
a central analysis of all neuroimaging studies. All
hemorrhages were classified using European Cooper-
ative Acute Stroke Study (ECASS) II27 definitions. For
cases where images could not be obtained, the origi-
nal radiology report was used to assess ICH. A third
neuroradiologist (EGH) adjudicated disagreements
between reviewers on presence or classification of
ICH.
Assessment of Stroke Severity and Functional Indepen-
dence. The National Institutes of Health Stroke Scale
(NIHSS) was used to assess pretreatment stroke sever-
ity and was obtained using two methods. First, the
medical record was reviewed and the pretreatment
score documented closest in time to the tPA bolus was
recorded, if available. No assessment of training or cer-
tification of the original hospital personnel document-
ing the NIHSS score was attempted. Second, study
coordinators certified in NIHSS assessment determined
an estimated pretreatment score using previously pub-
lished guidelines with formal decision rules on source
priority and score assignment.28
Functional independence was assessed with the mRS,
which uses an ordinal scale from ‘‘0’’ (normal) to ‘‘6’’
(death). Study coordinators determined the scores
using all available medical records and defined data
decision rules. Because this method has not previously
been described, we evaluated interrater agreement
on the sample of charts undergoing dual abstraction
compared to previously reported methods of mRS
assessment.
Outcome Measures
The primary outcome was all-cause mortality within
1 year of treatment, as determined by National Death
Index (NDI) query for patients treated from 1996 to
2003 and multistate vital statistics data for 2004 (NDI
data incomplete for 2004). Dates of death allowed anal-
ysis of mortality over time.
Secondary outcomes included occurrence of ICH.
Three a priori definitions of ICH within 36 hours of
treatment were assessed. First, ‘‘significant ICH’’ was
defined as a parenchymal hematoma exceeding 30% of
the infarct territory with substantial space-occupying
effect or any hemorrhagic lesion identified outside the
infarct area (parenchymal hemorrhage type-2 [PH-2] by
ECASS II criteria). This is the only type of post-tPA
treatment hemorrhage independently associated with
clinical deterioration and impaired prognosis.27 Second,
‘‘symptomatic ICH’’ was defined using two separate
clinical criteria: any ICH in patients not improved at
hospital discharge compared to condition at arrival or
any ICH accompanied by any documented transient or
permanent clinical decline. Third, ‘‘any ICH’’ included
any intracranial hemorrhage (symptomatic and asymp-
tomatic) identified within 36 hours of treatment. The
neuroimaging time was used as the time of hemorrhage
in all cases.
Other secondary safety outcomes included all-cause
mortality over time, major systemic hemorrhage, and
deviation from strictly interpreted institutional treatment
guidelines based on the NINDS tPA trial enrollment
criteria29 and the 1996 American Stroke Association30
recommendations. Determination of treatment guideline
deviation used explicit rules (i.e., a stroke onset-to-
treatment time of 181 minutes would be considered
a deviation). Specific criteria are listed in Data Supple-
ment S2. Measures of short-term neurologic disability,
an additional functional safety outcome, included
estimated mRS score at hospital discharge, and qualita-
tive assessment of discharge condition compared to
admission.
Data Analysis
Primary and secondary outcome measures, baseline
patient characteristics, and acute treatment elements
were summarized using descriptive statistics. Any
missing data were excluded from analysis. Any patient
identified as undergoing subsequent intraarterial
thrombolysis was excluded from the safety analysis.
Kappa coefficients were used to evaluate interrater
reliability.
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Comparisons were made using raw patient-level data
from the placebo and treatment groups in the original
NINDS tPA stroke study data.31 The NINDS tPA stroke
study was a randomized, placebo-controlled clinical
trial that established the efficacy of tPA as a treatment
for acute ischemic stroke when delivered by stroke spe-
cialists.29
Regression analyses and stepwise elimination were
used to explore the relationships between baseline
variables and the primary and secondary outcomes.
Baseline characteristics initially included were sex,
age (categorized into tertiles), onset to treatment time,
stroke severity, pretreatment blood pressure, pretreat-
ment glucose, treating hospital, and available aspects
of past medical history. Only the variables age, diabe-
tes, prior stroke, and stroke severity were significant
in at least one model. They were considered impor-
tant on general grounds and included in all final
models for adjustment purposes. Interactions between
these four variables and the group indicators (NINDS
tPA treatment, NINDS placebo, and the community
treatment cohorts) were tested and found to be non-
significant, and only main effects were included in the
final models. The main effect model was also tested
by incorporating all first-order interactions between
the adjustment covariates, and no lack of fit
was found except in the comparison of the commu-
nity treatment with the NINDS treatment group
for the mRS outcome. This is discussed further below.
The results reported are also robust to the choice of
the link function (e.g., probit and complementary
log-log).
All patients from both the NINDS treatment and the
placebo groups and community treatment cohort were
included in analyses examining mortality. Survival anal-
ysis was conducted using the Kaplan-Meier method.
Log-rank tests compared survival rates between the
study cohort and the NINDS treatment and control
groups at 3, 6, and 12 months following the index
stroke. Cox regression analysis provided relative risks
(RRs) for mortality adjusted for differences in baseline
characteristics between the community treatment
cohort and the NINDS tPA treatment and control
cohorts.
In analyses examining ICH, the occurrence of ‘‘signif-
icant ICH’’ in the community-treated cohort was speci-
fied a priori for comparison to the occurrence of
symptomatic ICH within 36 hours of treatment in the
NINDS tPA-treated group. Unadjusted comparisons
used chi-square tests. Standard logistic regression
models were used to make adjusted comparisons.
Standard logistic regression models were also used
to make adjusted comparisons in analyses examining
functional neurological recovery. The model estimated
odds of early functional recovery (defined as an mRS
score £ 2) versus a poor outcome (mRS > 2). An mRS
score of ‘‘2’’ represents a patient with ‘‘slight disability;
unable to carry out all previous activities but able to
look after own affairs without assistance.’’32 Functional
neurologic recovery was defined as an mRS score £ 2
because early (7-day posttreatment) mRS scores of 0–2
more closely approximate ultimate (90-day posttreat-
ment) mRS outcomes of 0–1.31,33
Comparison was specified a priori between the mRS
score at hospital discharge in the community-treated
cohort, and the 7- to 10-day mRS score obtained post-
treatment in both the NINDS treatment and the placebo
cohorts. The NINDS tPA treatment cohort, but not the
placebo cohort, was restricted in the model to subjects
treated between 91 and 180 minutes to increase homo-
geneity to the community treated cohort. To include
only patients with the potential to meet the study defini-
tion of functional recovery (mRS £ 2), subjects from
both the NINDS groups and the community treatment
cohorts with a prestroke mRS of ‡ 2 were excluded
from the model. There was some indication of an inter-
action between age and diabetes in the model for mRS
comparing community treatment and NINDS treatment.
This interaction did not affect the treatment compari-
son, however, and because it arose only in this model
we took the simpler route of reporting only main effect
models in all cases. All analyses were conducted using
SAS (Version 9.1.3, SAS Institute, Cary, NC).
RESULTS
EP Experience
Ninety-five individual EPs treated 273 patients with tPA
for acute ischemic stroke during the 9-year study per-
iod. Two patients received combination therapy with IV
tPA followed by intraarterial tPA at a tertiary center.
The maximum number of patients treated by a single
physician was 13. The median number of treatments
per physician was two (interquartile range [IQR] = 1–
3.5), the mode was one, and the mean ± SD was
2.9 ± 2.61 patients per physician. Seventy-six percent of
treated cases had a documented neurology consultation
(40% in person, 36% by phone).
Twenty-eight patients were initially seen at 13 other
smaller regional hospitals, and 22 were treated with
tPA prior to transfer to one of the four study hospitals.
Transferred patients were attributed to their destination
hospital for analysis (see Table 1 for treatment data by
hospital).
Data Quality
Source data acquisition was excellent, with all identified
medical records reviewed. All data concerning a priori
specified critical elements were obtained, with nine
exceptions (eight posttreatment blood pressure mea-
surements, one premature use of antiplatelet therapy).
In 86% of patients, all original CT and MRI images per-
formed within the first 10 days following treatment
were obtained. Copies of the original neuroradiology
interpretations were obtained for all images in 100% of
patients.
Dual data abstraction was performed on 29% of
charts (over sampled). Raw interrater agreements for
prespecified critical and noncritical data elements were
99 and 96%, respectively. With respect to interrater
agreement for the estimation of the mRS, there were
four reviewers involved, and the dual abstractions cor-
responded primarily to four separate pairs of review-
ers. The weighted average of weighted kappa statistics
indicated acceptable agreement (0.74, 95% confidence
interval [CI] = 0.68 to 0.80) and was consistent with
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previously reported agreement obtained from mRS
assessment using a structured interview process.32
Patient Characteristics
Patient demographics and baseline characteristics are
presented in Table 2 and were generally similar to those
in the NINDS study. There was a higher proportion of
non-Hispanic whites, as well as patients with preexisting
disability, in the community-treated cohort. In the com-
munity cohort, 81 of 273 patients (30%) had an mRS
score ‡ 2 prior to their presenting stroke, compared to
48 of 624 patients (8%) in the NINDS tPA study. The esti-
mated presenting NIHSS mean ± SD score was 13 ± 6.
The median was 13 (IQR = 8–17). The distribution of
NIHSS scores is presented in Figure 1A. In the 168
patients with documented presenting NIHSS scores, the
mean ± SD was 14 ± 7 and the median was 14 (IQR =
8–19).
Mean ± SD time from onset to treatment was
154 ± 32 minutes (median = 160; IQR = 133–176). The
distribution of time from onset to treatment for patients
in this cohort is similar to those in the NINDS 91- to
180-minute treatment group (Figure 1B). Only four
patients in the study cohort were treated within 90 min-
utes of stroke onset.
Occurrence of major systemic hemorrhage (requiring
transfusion) was 1.1%. In the NINDS trial, this occur-
rence was 1.6% (5 of 312 patients).
Mortality
The primary endpoint, mortality at 1 year, was 27.8%,
consistent with that in the NINDS tPA treatment group
(24.4%; absolute difference = 3.5%, 95% CI = )3.7% to
10.6%) and the NINDS placebo group (27.6%; absolute
difference = 0.2%, 95% CI = )7.0% to 7.5%). The 3- and
6-month community treatment mortality rates (22.7 and
25.3%, respectively) were also consistent with the
NINDS tPA treatment group (17 and 21%) and NINDS
placebo group (21 and 23%). Figure 2A shows survival
curves from the Kaplan-Meier analyses and group com-
parisons. There were no significant differences between
the curves.
Unadjusted Cox model RR for mortality at 1 year
was 1.20 (95% CI = 0.87 to 1.64) in the study cohort
compared to the NINDS tPA group and 1.04 (95%
CI = 0.76 to 1.41) compared to the NINDS placebo
group. In the Cox regression analysis of survival,
patients who were older, diabetic, or had higher
baseline stroke severity (NIHSS score) were at greater
risk for death at 12 months. Having adjusted for those
covariates, there were still no significant differences
in mortality risk among the three groups (commu-
nity treatment, NINDS treatment, NINDS placebo; see
Table 3).
In-hospital mortality among community-treated
patients, a potential signal of treatment complications,
was consistent with both NINDS treatment and placebo
Table 2









Age (yr) 68 ± 15 68 ± 11 66 ± 12
Race or ethnic group (%)
White, non-Hispanic 86 66 63
Black or African American 11 26 29
Hispanic 1 6 6
Asian 1 2 0
Other 2 0 2
Female sex (%) 45 43 41
Medical histories (%)
Stroke 16 14 12
TIA 15 17 17
Diabetes 22 22 20
Hypertension 72 67 66
Atrial fibrillation 23 19 18
Congestive heart failure 11 15 18
Valvular heart disease 8 8 6
Smoking in year before stroke 27 34 36
Antiplatelet drug use 43 41 29
NIHSS (estimated)
Median 13 14 15
Minimum 2 1 1
First quartile 8 8 9.75
Third quartile 17 19 20
Maximum 32 37 33
Blood pressure (mm Hg)
Systolic 150 ± 22 154 ± 22 153 ± 21
Diastolic 77 ± 15 85 ± 13 86 ± 13
Glucose (mg ⁄ dL) 131 ± 51 149 ± 71 151 ± 78
NIHSS = National Institutes of Health Stroke Scale; TIA = transient ischemic attack; tPA = tissue plasminogen activator.
*Plus–minus values are means ± SD. Because of rounding, not all columns total 100%.
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groups with 13.2, 10.9, and 12.5% of patients dying
prior to discharge, respectively.
ICH
In the community-treated cohort, the proportion of sig-
nificant ICH within 36 hours of treatment by CT criteria
(ECASS PH-2) was 6.6% (odds ratio [OR] 1.03, 95%
CI = 0.53 to 1.98 compared to the NINDS tPA treatment
group with symptomatic hemorrhage within 36 hours).
The proportions of symptomatic ICH by the other pre-
specified clinical criteria were 4.8% (any ICH within
36 hours of treatment in patients not improved at hos-
pital discharge) and 7.0% (any ICH within 36 hours of
treatment preceded by any documented transient or
permanent clinical decline). The proportion of any ICH
(symptomatic and asymptomatic) within 36 hours of
treatment was 9.9% (OR = 0.94, 95% CI = 0.58 to 1.51,
compared to NINDS tPA treatment group). These unad-
justed secondary safety measures were consistent with
the experience of the NINDS trial, where the propor-
tions of symptomatic and total ICH within 36 hours of
treatment were 6.4 and 10.9%, respectively.
In the binary logistic regression model for estimating
the odds of having a significant hemorrhage (PH-2),
patients over 80 years of age (highest tertile) were
found to have greater risk compared to those ages
63 years or younger (lowest tertile). After adjusting for
these variables, there was still no significant difference
in the incidence of symptomatic hemorrhage in those
treated with tPA in the NINDS trial compared to the
incidence of significant hemorrhage (PH-2) in the com-
munity cohort (Table 3). No interactions between base-
line variables and the NINDS tPA treatment group
were detected.
tPA Use Guideline Deviations
Guideline deviations occurred in the ED in 26% (n = 71)
of patients (61% treated beyond 3 hours; 11% hyper-
tension; 7% each thrombocytopenia, hypoglycemia, or
seizure). Among the 46 patients treated beyond 180
minutes, the median time beyond the treatment window
was 15 minutes (IQR = 5–20 minutes). In nine (20%) of
these patients, there was specific acknowledgement or
consent documented in the chart regarding treatment
beyond 180 minutes. Following admission, guideline
deviations occurred in 25% of patients in the first 24
hours (36% blood pressure violations, 39% premature
[<24 hours] use of antiplatelet agents, 25% premature
use of anticoagulants).
Neurologic Recovery
In evaluating neurologic recovery, 192, 138, and 288
patients from the community treatment, NINDS tPA
treatment, and NINDS placebo cohorts met the speci-
fied time and prestroke mRS exclusion criteria for
inclusion in the regression model (see Data Analysis for
further detail).
The mRS scores at discharge are presented by cohort
in Figure 2B. Complete or near-complete functional
neurologic recovery (mRS 0 to 2 at discharge—mean ±
SD 8 ± 7.7 days posttreatment; median 6 days; IQR =
4–9 days) was achieved in 38% of patients with pre-
morbid disability mRS scores < 2. In both the un-
adjusted and the adjusted models, the chance of early
functional neurologic recovery was not significantly
different in the community-treated cohort compared to
the NINDS placebo group or the comparison NINDS
tPA treatment group (Table 3). Patients who were older
and had more severe strokes were at greater risk for
poor outcomes.
Qualitative condition at discharge relative to stroke
presentation, as determined by the study coordinators,
was as follows: normal (11%), improved (64%),
unchanged (6%), worse (7%), and dead (13%). Dis-
charge disposition was home (38%), rehabilitation
(30%), assisted living or nursing home (16%), other
acute care hospital (3%), and death (13%).
DISCUSSION
This population-based study of stroke treatments at
four community hospitals in a four-county region exem-
plifies the ‘‘community model’’ of acute stroke care, in
which a large number of EPs treated patients with tPA
using standard neurology consulting practices and pro-
tocols. Consequently, the individual experience of most
EPs was limited.
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Figure 1. Patient Characteristics. (A) Distribution of the
National Institutes of Health Stroke Scale (NIHSS) scores. (B)
Distribution of time from stroke onset to treatment.
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A. Survival curves for study and NINDS cohorts
B. Proportion of Functional Outcomes by mRS for study and NINDS cohorts*
Absolute number of scores in each mRS category overlaid on chart bars.
* Distribution of discharge (mean 8 days) modified Rankin scores in the study cohort compared to those measured at
7-10 days in the NINDS trial. Excludes subjects in all cohorts with pre-stroke mRS > 1. Includes all NINDS subjects
treated at 91 – 180 minutes (1 tPA and 3 placebo treated patients excluded from NINDS groups due to missing data).
Figure 2. Patient outcomes. (A) Survival curves for study and National Institute of Neurological Disorders and Stroke (NINDS)
cohorts. (B) Functional outcomes for study and NINDS cohorts. *Distribution of discharge (mean ± SD = 8 ± 8 days) modified
Rankin Scale (mRS) scores in the study cohort compared to those measured at 7–10 days in the NINDS trial. Excludes subjects in
all cohorts with prestroke mRS > 1. Includes all NINDS subjects treated at 91–180 minutes (one tPA- and three placebo-treated
patients excluded from NINDS groups due to missing data).
Table 3










One-year mortality (Cox model), RR (95% CI) 1.20 (0.87–1.64) 1.04 (0.76–1.41) 1.25 (0.90–1.75) 1.09 (0.79–1.52)
ICH (sICH within 36 hr), OR (95% CI) 1.03 (0.53–1.98) 1.02 (0.51–2.07)
Functional recovery (mRS £ 2), OR (95% CI) 0.83 (0.53–1.29) 1.46 (0.99–2.15) 0.67 (0.39–1.16) 1.07 (0.67–1.70)
ICH = intracerebral hemorrhage; mRS = modified Rankin Scale; NINDS = National Institute of Neurological Disorders and Stroke;
OR = odds ratio; RR = relative risk; sICH = significant ⁄ symptomatic intracerebral hemorrhage; tPA = tissue plasminogen activator.
*Outcomes adjusted for baseline variables: age, diabetes, stroke severity, and prior stroke.
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These data fail to provide evidence that tPA delivery
in this cohort is less safe than delivery by the special-
ized acute stroke teams in the NINDS tPA stroke study.
Safety was confirmed on both primary and secondary
outcome measures. Survival at 1 year, nearly identical
in our cohort to that in the NINDS tPA trial, was
selected as the primary outcome because it is intuitively
important, patient-oriented, objective, and reliably
obtained. The 1-year survival curve for the community
treatment cohort was not significantly different from
those of the NINDS tPA treatment group or the NINDS
placebo group.34
The proportion of tPA-associated ICH is an important
secondary outcome, because physician concern over
this complication reinforces barriers to acceptance of
thrombolytic use in stroke, including physician agree-
ment, motivation, and outcome expectancy. Addressing
these barriers is essential to adoption of new treatment
guidelines and necessary for effective knowledge trans-
lation to broaden community usage.35 Our ICH findings
are in clear contrast to data from substantially smaller
case series that suggested the occurrence of post-
treatment ICH may be unacceptably high in community
practice, where experience may be diluted among a
larger number of providers.4,11,18
We found a lower proportion of total (symptomatic
and asymptomatic) ICH in the study cohort compared
to the NINDS treatment group. This may be an artifact
resulting from mandatory repeat CT scanning in the
NINDS study, but not in clinical practice. In the com-
munity-treated cohort, 82% of all patients underwent
posttreatment neuroimaging. The likelihood that some
entirely asymptomatic ICH was missed probably high-
lights the lack of clinical relevance of this measure.
Of greater importance is the proportion of significant
or symptomatic hemorrhage, which was conservatively
defined using one imaging and two clinical criteria in
this study. The findings were robust, with all three mea-
sures consistent with those in the NINDS tPA stroke
study. It is unlikely that substantial numbers of patients
with significant or symptomatic ICH were missed due
to lack of repeat neuroimaging given the high mortality
(61% at 90 days) associated with symptomatic ICH in
the NINDS tPA stroke study and our findings of equiva-
lent 90-day posttreatment mortality. Patients with good
neurologic outcomes were most likely not to have
follow-up neuroimaging performed. Patients who were
dead at hospital discharge were least likely to not
have follow-up neuroimaging (three patients).
The prevalence of guideline deviations is a process-
oriented secondary outcome measure and was found to
be considerable. This represents an opportunity for
improvement through systems of quality management
and continuing education. The most prevalent guideline
deviation in the ED was treatment outside the 3-hour
window. Although 20% of these violations were docu-
mented as deliberate, the vast majority were not. Simi-
larly, while a third of the out-of-window treatments
were less than 5 minutes late, defined by the most con-
servative estimate of time-last-seen-normal, many were
substantially greater.
Given the other safety outcomes and recently pub-
lished data suggesting safety and efficacy of tPA use in
stroke between 3 and 4.5 hours from onset,36 the clini-
cal implications of these violations seems limited, but
suggest a continuing need for process improvement.
Our data offer new insight into the frequency of devia-
tions from accepted postthrombolytic treatment guide-
lines in the critical first 24 hours and emphasize
extending efforts on guideline adherence to the inpa-
tient setting.
In addition to meeting the mortality and ICH criteria
for safety, the community treatment cohort also demon-
strated safety in functional disability, which, measured
conservatively, was not worse than the NINDS placebo
group. This methodology was explicitly designed to
determine safety and not to look for signals of efficacy. It
was therefore conservatively biased against demonstra-
ting improvements compared to the NINDS placebo
group. This bias was manifest in the use of short-term
rather than 90-day post-treatment outcomes and in the
adjusted analysis by the assumption that all undocu-
mented portions of the NIHSS were normal. Although
limited in this manner, the unadjusted data do suggest—
but cannot confirm—better functional recovery in the
community delivery of tPA cohort compared to placebo
in the NINDS trial.
LIMITATIONS
This study was designed to evaluate safety rather than
efficacy. Ultimately, safety is most important when con-
sidered in the context of the potential for clinical recov-
ery. Data indicate, however, that EP concerns regarding
use of tPA in stroke focus primarily on safety, parti-
cularly risk of ICH.37 The study’s retrospective design
allows robust evaluation of multiple safety measures,
but only limited confidence in outcome data related to
efficacy.
Assessment of efficacy in this cohort is quite limited
due to the lack of uniform measures of long-term out-
come. Estimations of NIHSS, an important variable in
all of the adjusted analyses, were biased toward lower
scores as any component not explicitly charted was
assumed normal. This may explain differences found
between the unadjusted and adjusted analyses. Retro-
spective estimation of mRS score is common, but has
not been previously validated and interrater agreement
was modest. Agreement for mRS scores between
reviewers in our study was comparable to an accepted
structured interview process, although the potential for
substantial variation remains. Additionally, because
estimations of mRS in this study were performed at
hospital discharge, they may be higher and more vari-
able than at 90 days posttreatment, a common stroke
outcome assessment point.
In the regression models, it was not possible to
adjust for treatment clustering by physician given the
small number of treatments per physician in the study
data set and the use of historical NINDS data. Although
treatment hospital was included in the initial model it
was dropped for lack of effect; this may incompletely
account for potential clustering of patients within hos-
pitals in the final model.
An additional potential limitation involves the inclu-
sion of 22 patients who were treated with IV tPA at
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EDs elsewhere and immediately transferred to one of
the four study hospitals. Reanalysis excluding these
patients did not change any of the findings (see Data
Supplement S1, Table, for further detail on the
results).
Another potential limitation is that the cohorts com-
pared are sequential rather than contemporaneous
(1991 to 1994 for the NINDS study and 1996–2005 for
this observational study).
Finally, while these findings represent the largest ser-
ies to date of patients treated without an acute throm-
bolytic team, care should be taken in generalizing the
findings. The absolute number of hospitals in the cohort
is small, and the participating hospitals have varying
levels of affiliation with an academic medical center
with an emergency medicine residency and a strong
interest in stroke.
CONCLUSIONS
In this cohort, there was no evidence of increased risk
when tPA use in stroke was directed by EPs, using pro-
tocols and available neurology consultation methods, in
hospitals without acute thrombolytic stroke teams.
Additional work is needed to improve guideline compli-
ance both in the ED and in inpatient settings and to
increase speed of delivery.
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